Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats

Autor(es):Mostrar menos -

Faverani, Leonardo Perez ^{[1, 2]} ; Braga Polo, Tarik Ocon ^{[1, 2]} ; Ramalho-Ferreira, Gabriel ^{[1, 2]} ; Correa Momesso, Gustavo Antonio ^{[1, 2]} ; Hassumi, Jaqueline Suemi ^{[1, 2, 3]} ; Rossi, Ana Claudia ^[4] ; Freire, Alexandre Rodrigues ^[4] ; Prado, Felippe Bevilacqua ^[4] ; Luvizuto, Eloa Rodrigues ^{[1, 5]} ; Gruber, Reinhard ^[6] ; Okamoto, Roberta ^[3]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ UNESP, Dept Surg, Sch Dent, BR-16015050 Sao Paulo - Brazil

^[2] Sao Paulo State Univ UNESP, Sch Dent, Div Oral & Maxillofacial Surg, Integrated Clin, BR-16015050 Sao Paulo - Brazil

^[3] Sao Paulo State Univ UNESP, Sch Dent, Dept Basic Sci, BR-16015050 Sao Paulo - Brazil

^[4] Univ Campinas UNICAMP, Piracicaba Dent Sch, Dept Morphol, Piracicaba, SP - Brazil

^[5] Sao Paulo State Univ UNESP, Sch Dent, Div Integrated Clin, Integrated Clin, BR-16015050 Sao Paulo - Brazil

^[6] Med Univ Vienna, Dept Oral Biol, Vienna - Austria

• Tipo de documento: Artigo Científico
• Fonte: CLINICAL ORAL INVESTIGATIONS; v. 22, n. 1, p. 255-265, JAN 2018.
• Citações Web of Science: 9

Resumo

Alendronate and raloxifene, a bisphosphonate and a selective estrogen modulator, respectively, are established osteoporosis therapies. Current evidence suggests that simultaneous application of osteoporosis therapies modulates osseointegration. However, alendronate shows inconsistent findings and raloxifene has not been studied comprehensively. This study aimed to evaluate the bone dynamics and molecular and microstructural features at the peri-implant bone interface in osteoporotic rats. Thirty female rats underwent ovariectomy and were fed a diet low in calcium and phosphate and treated with alendronate or raloxifene for 30 days or underwent fictional ovariectomy surgery (SHAM) prior to implant insertion in the tibia; osteoporosis therapies continued thereafter. After 42 days, peri-implant bone was evaluated by histometric and micro-CT analysis. Fluorochrome incorporation and gene expression was determined to evaluate bone turnover. We report here that alendronate had no impact on bone-to-implant contacts and the mineral apposition rate. The RANKL/OPG ratio and local bone volume, however, were increased compared to the untreated osteoporotic rats. Even though signaling to bone resorption activity through RANKL production was observed in the alendronate group, the blockade of bone resorption activity that occurs in decorrence to alendronate activity took place and resulted in an increase in bone volume. Raloxifene significantly increased osseointegration in osteoporotic rats, as indicated by bone-to-implant contacts, mineral apposition, and local bone volume. Raloxifene, however, had no considerable impact on the RANKL/OPG ratio compared to untreated osteoporotic rats. As expected, the SH group showed higher bone-to-implant contacts and mineral apposition rates than the untreated osteoporotic rats. These findings suggest that raloxifene but not alendronate can compensate for the impaired osseointegration in osteoporotic rats. Regarding the superiority of raloxifene observed in the improvement of bone dynamics response, this statement suggests that raloxifene could be a good option for osteoporosis patients in oral rehabilitation procedures. (AU)

• Processo FAPESP: 12/15912-2 - Avaliação do reparo ósseo na interface osso / implante em ratas com osteoporose induzida tratadas com raloxifeno ou alendronato: análise histométrica, imunoistoquímica, por epifluorescência e biomecânica
• Beneficiário: Roberta Okamoto
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 12/15748-8 - Avaliação do reparo ósseo na interface osso/implante em ratas com osteoporose induzida tratadas com raloxifeno ou alendronato - Análise histométrica, imunoistoquímica, por epifluorescência e biomecânica
• Beneficiário: Gabriel Ramalho Ferreira
• Modalidade de apoio: Bolsas no Brasil - Doutorado